Collegium to acquire AZSTARYS from Corium Therapeutics

Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease

GenomOncology partners with WeTrials to support CNS cancer clinical trials

Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis

Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial

Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research

Guerbet's contrast agent Elucirem approved by European Commission in children from birth

Insilico Medicine signs co-development collaboration agreement with Hygtia Therapeutics

Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)

Hemispherian secures US patent allowance expanding GLIX1 patent protection

MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS

Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation

MapLight Therapeutics commences IPO

SineuGene Therapeutics' ALS drug Investigational New Drug application receives Chinese regulatory approval

South Rampart Pharma reports new study findings showing SRP-001 delivers central, non-toxic pain relief